Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSV: NGEN )

2.900 -0.130 (-4.29%)
Streaming Delayed Price Updated: 3:41 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,500
Open 3.000
Bid (Size) 2.880 (10)
Ask (Size) 2.900 (10)
Prev. Close 3.030
Today's Range 2.890 - 3.000
52wk Range 1.580 - 3.980
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
+17.41%
+17.41%
1 Month
+2.84%
+2.84%
3 Month
+39.42%
+39.42%
6 Month
-12.65%
-12.65%
1 Year
+55.91%
+55.91%

More News

Read More
NervGen Pharma Announces Leadership Transition
Via Newsfile
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Via Newsfile
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Via Newsfile
Exposures COVID-19
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports First Quarter 2021 Results
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Via Newsfile
Exposures COVID-19
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports 2020 Year End Results
Via Newsfile
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.